Capricor Q2 Loss Widens to $40.7M; New HQ Lease and Insider Selling Plans Disclosed
CAPR has more than doubled off its 52-week low of $2.96 on elevated volume (16× avg).
Summary
Capricor reported a wider Q2 loss and disclosed a major new headquarters lease, insider selling plans, and new litigation, all while facing an FDA advisory committee's negative vote on its lead drug.
Key Events · Earnings and Guidance · CAPR
-
Q2 Loss Widens to $40.7M
Net loss increased 57% year-over-year to $40.7M, driven by a 148% jump in G&A expenses to $14.1M as the company ramps pre-commercial activities.
-
Cash Position Declines to $237.9M
Cash, equivalents, and marketable securities fell from $318.1M at year-end to $237.9M, though management states this funds operations for at least 12 months.
-
New Headquarters Lease Signed
Capricor entered a lease for 171,001 sq ft in San Diego with $31.6M in tenant improvement allowances and initial monthly base rent of $958K, contingent on FDA approval of deramiocel.
-
Five Directors Adopt 10b5-1 Selling Plans
Directors adopted trading plans covering up to 442,826 shares, with expiration dates ranging from December 2026 to July 2027.
Analysis · CAPR · Life Sciences
Capricor's Q2 loss widened to $40.7M from $25.9M a year ago, driven by a 148% surge in G&A expenses as the company prepares for potential commercialization of deramiocel. Cash and marketable securities fell to $237.9M from $318.1M at year-end, though management says this funds operations for at least 12 months. The filing also reveals a major new headquarters lease with $31.6M in tenant improvement allowances and five directors adopting 10b5-1 trading plans covering up to 442,826 shares. These disclosures come amid an FDA advisory committee's 9-3 vote against deramiocel's effectiveness for cardiomyopathy and a new patent infringement lawsuit from Mesoblast.
At the time of this filing, CAPR was trading at $6.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $385.1M. The 52-week trading range was $2.96 to $40.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.